Physician profile
Reginald Sandy
NPI 1972504629
$3,623.39
in general payments reported to CMS, 2019-2025
26 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $221 · 2021: $346 · 2022: $469 · 2023: $439 · 2024: $788 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288 · Education: $21.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.13 |
| Education | $21.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $656.15 | 2019-2025 | Creon, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $626.81 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $558.16 | 2022-2025 | Tremfya, Stelara |
| Celgene Corporation | $490.11 | 2022-2024 | Zeposia |
| Pfizer INC. | $202.57 | 2019-2025 | |
| Ardelyx, INC. | $167.37 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $138.92 | 2019-2022 | |
| Medtronic, INC. | $89.61 | 2022 | |
| Braintree Laboratories, INC. | $84.52 | 2020-2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $84.44 | 2019-2023 | Dupixent |
| Madrigal Pharmaceuticals | $79.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $66.95 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $62.33 | 2024-2025 | Voquezna |
| Echosens North America, INC. | $54.48 | 2021 | |
| Intercept Pharmaceuticals, INC. | $52.11 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.28 | 2025 | Xifaxan |
| Celltrion USA INC. | $21.04 | 2024 | Zymfentra |
| Melinta Therapeutics, LLC | $21.01 | 2022 | |
| Daiichi Sankyo INC. | $19.97 | 2022 | |
| Lilly USA, LLC | $15.86 | 2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $15.71 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $15.55 | 2025 | Blueboost |
| Ferring Pharmaceuticals INC. | $15.06 | 2024 | Rebyota |
| Axonics, INC. | $14.99 | 2021 | |
| Olympus America INC. | $14.43 | 2019 | |
| Allergan, INC. | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reginald Sandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.